Clinical Research Directory
Browse clinical research sites, groups, and studies.
Early Triple Lipid-Lowering Therapy With Bempedoic Acid After Acute Coronary Syndrome
Sponsor: Taipei Medical University Hospital
Summary
This randomized clinical trial will evaluate whether starting bempedoic acid in addition to high-intensity statin therapy and ezetimibe within 72 hours after percutaneous coronary intervention improves low-density lipoprotein cholesterol (LDL-C) control in adults with acute coronary syndrome. Participants will receive either triple therapy with a high-intensity statin, ezetimibe, and bempedoic acid or standard dual therapy with a high-intensity statin and ezetimibe for 12 weeks. The primary outcome is the proportion of participants with LDL-C below 55 mg/dL at Week 12. Changes in lipid and inflammatory markers, medication adherence, and treatment-emergent adverse events will also be assessed.
Official title: EARLY-BIRD ACS Trial: Early Aggressive Lipid-Lowering Regimen With Bempedoic Acid Initiated for Reducing Dyslipidemia in Patients With Acute Coronary Syndrome
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
400
Start Date
2026-08-26
Completion Date
2028-12
Last Updated
2026-09-17
Healthy Volunteers
No
Conditions
Interventions
bempedoic acid
Bempedoic acid 180 mg tablet taken orally once daily for 12 weeks.
Ezetimibe
Ezetimibe 10 mg tablet taken orally once daily for 12 weeks.
High-Intensity Statin Therapy
Atorvastatin 40 mg orally once daily or rosuvastatin 20 mg orally once daily for 12 weeks, selected according to clinical judgment and routine practice.
Locations (1)
Taipei Medical University Hospital
Taipei, Taipei City, Taiwan